Luye Pharma Group Ltd.

DB:LUP Stock Report

Market Cap: €1.0b

Luye Pharma Group Valuation

Is LUP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LUP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LUP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LUP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LUP?

Key metric: As LUP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LUP. This is calculated by dividing LUP's market cap by their current earnings.
What is LUP's PE Ratio?
PE Ratio10x
EarningsCN¥770.46m
Market CapCN¥7.69b

Price to Earnings Ratio vs Peers

How does LUP's PE Ratio compare to its peers?

The above table shows the PE ratio for LUP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.7x
DMP Dermapharm Holding
23.2x17.3%€2.1b
PSG PharmaSGP Holding
17.1x14.1%€321.3m
93M1 MPH Health Care
0.8x-65.7%€97.6m
MRK Merck KGaA
21.8x10.2%€58.8b
LUP Luye Pharma Group
10x14.4%€8.2b

Price-To-Earnings vs Peers: LUP is good value based on its Price-To-Earnings Ratio (10x) compared to the peer average (15.7x).

Price to Earnings Ratio vs Industry

How does LUP's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
LUP 10.0xIndustry Avg. 22.1xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: LUP is good value based on its Price-To-Earnings Ratio (10x) compared to the European Pharmaceuticals industry average (22.1x).

Price to Earnings Ratio vs Fair Ratio

What is LUP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LUP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10x
Fair PE Ratio14.1x

Price-To-Earnings vs Fair Ratio: LUP is good value based on its Price-To-Earnings Ratio (10x) compared to the estimated Fair Price-To-Earnings Ratio (14.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LUP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.27
€0.43
+61.3%
15.7%€0.50€0.36n/a4
Feb ’26€0.26
€0.43
+66.3%
15.7%€0.50€0.36n/a4
Jan ’26€0.26
€0.43
+63.8%
15.7%€0.50€0.36n/a4
Dec ’25€0.30
€0.43
+45.7%
12.5%€0.47€0.36n/a3
Nov ’25€0.33
€0.43
+30.0%
12.5%€0.47€0.36n/a3
Oct ’25€0.38
€0.42
+8.8%
15.5%€0.46€0.32n/a3
Sep ’25€0.35
€0.42
+21.0%
15.1%€0.47€0.33n/a3
Aug ’25€0.33
€0.36
+10.6%
21.7%€0.47€0.28n/a3
Jul ’25€0.31
€0.36
+15.3%
21.4%€0.47€0.29n/a3
Jun ’25€0.31
€0.36
+15.3%
21.4%€0.47€0.29n/a3
May ’25€0.32
€0.36
+10.7%
22.3%€0.47€0.29n/a3
Apr ’25€0.32
€0.41
+31.3%
29.4%€0.59€0.28n/a4
Mar ’25€0.34
€0.41
+21.1%
29.3%€0.59€0.28n/a4
Feb ’25€0.30
€0.40
+32.2%
30.7%€0.59€0.28€0.264
Jan ’25€0.43
€0.34
-20.5%
20.8%€0.44€0.28€0.263
Dec ’24€0.45
€0.34
-24.8%
20.8%€0.44€0.28€0.303
Nov ’24€0.45
€0.35
-22.3%
18.7%€0.44€0.29€0.333
Oct ’24€0.42
€0.35
-18.1%
19.1%€0.44€0.28€0.383
Sep ’24€0.33
€0.37
+10.2%
19.8%€0.45€0.28€0.354
Aug ’24€0.42
€0.41
-2.1%
31.2%€0.60€0.28€0.334
Jul ’24€0.38
€0.38
+1.1%
37.9%€0.60€0.24€0.314
Jun ’24€0.41
€0.40
-2.9%
33.6%€0.63€0.25€0.315
May ’24€0.44
€0.40
-7.9%
33.7%€0.63€0.25€0.325
Apr ’24€0.42
€0.39
-8.2%
41.2%€0.65€0.24€0.325
Mar ’24€0.44
€0.39
-11.5%
41.2%€0.65€0.24€0.345
Feb ’24€0.47
€0.39
-18.3%
41.2%€0.65€0.24€0.305
Analyst Price Target
Consensus Narrative from 4 Analysts
€0.42
Fair Value
36.9% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/11 01:35
End of Day Share Price 2025/02/11 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Luye Pharma Group Ltd. is covered by 21 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Jessica LiBofA Global Research
Lok Kwan ChiuCCB International Securities Limited